WO2016059269A8 - Compuestos derivados de acrilato de 3-alouilamino-1h- indolilo y su uso en el tratamiento de enfermedades neurodegenerativas - Google Patents

Compuestos derivados de acrilato de 3-alouilamino-1h- indolilo y su uso en el tratamiento de enfermedades neurodegenerativas Download PDF

Info

Publication number
WO2016059269A8
WO2016059269A8 PCT/ES2015/000139 ES2015000139W WO2016059269A8 WO 2016059269 A8 WO2016059269 A8 WO 2016059269A8 ES 2015000139 W ES2015000139 W ES 2015000139W WO 2016059269 A8 WO2016059269 A8 WO 2016059269A8
Authority
WO
WIPO (PCT)
Prior art keywords
alkylamino
treatment
disease
neurodegenerative diseases
compounds derived
Prior art date
Application number
PCT/ES2015/000139
Other languages
English (en)
French (fr)
Other versions
WO2016059269A1 (es
Inventor
Rafael Leon Martinez
Izaskun Buendia Abaitua
Ellsa NAVARRO GONZALEZ DE MESA
Patrycja MICHALSKA
Isabel GAMEIRO ROS
Alicia LÓPEZ VIVO
Javier Egea Maiquez
Manuela Garcia Lopez
Antonio Garcia Garcia
Original Assignee
Fundacion Para La Investigacion Biomedica Del Hospital Universitario De La Princesa
Universidad Autonoma De Madrid
Dns Neuroscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Para La Investigacion Biomedica Del Hospital Universitario De La Princesa, Universidad Autonoma De Madrid, Dns Neuroscience filed Critical Fundacion Para La Investigacion Biomedica Del Hospital Universitario De La Princesa
Priority to CA2964309A priority Critical patent/CA2964309A1/en
Priority to EP15851060.2A priority patent/EP3208262A4/en
Priority to US15/518,223 priority patent/US20180105492A1/en
Publication of WO2016059269A1 publication Critical patent/WO2016059269A1/es
Publication of WO2016059269A8 publication Critical patent/WO2016059269A8/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a los métodos de obtención de derivados de acrilato de 3-aIquilamino- 1H-indolilo (I) con actividad inductora del factor de transcripción Nrf2, actividad secuestradora de radicales libres y capacidad neuroprotectora. Otro aspecto de la invención se refiere al uso de los derivados objeto de esta invención para el tratamiento de enfermedades en cuya patogénesis interviene el de estrés oxidativo o enfermedades que cursen con desregulación de la actividad de genes de fase dos activados por el factor Nrf2, como la enfermedad de Alzheimer, la enfermedad de Parkinson, la enfermedad de Huntington, la esclerosis múltiple, el ictus o la esclerosis lateral amiotrófica.
PCT/ES2015/000139 2014-10-15 2015-10-15 Compuestos derivados de acrilato de 3-alouilamino-1h- indolilo y su uso en el tratamiento de enfermedades neurodegenerativas WO2016059269A1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2964309A CA2964309A1 (en) 2014-10-15 2015-10-15 Compounds derived from 3-alkylamine-1h-indolyl acrylate and their use in the treatment of neurodegenerative diseases
EP15851060.2A EP3208262A4 (en) 2014-10-15 2015-10-15 Compounds derived from 3-alkylamino-1h-indole acrylate, and the use thereof in the treatment of neurodegenerative diseases
US15/518,223 US20180105492A1 (en) 2014-10-15 2015-10-15 Compounds derived from 3-alkylamine-1h-indolyl acrylate and their use in the treatment of neurodegenerative diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201400810A ES2570452B1 (es) 2014-10-15 2014-10-15 Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
ESP201400810 2014-10-15

Publications (2)

Publication Number Publication Date
WO2016059269A1 WO2016059269A1 (es) 2016-04-21
WO2016059269A8 true WO2016059269A8 (es) 2017-05-26

Family

ID=55746171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2015/000139 WO2016059269A1 (es) 2014-10-15 2015-10-15 Compuestos derivados de acrilato de 3-alouilamino-1h- indolilo y su uso en el tratamiento de enfermedades neurodegenerativas

Country Status (5)

Country Link
US (1) US20180105492A1 (es)
EP (1) EP3208262A4 (es)
CA (1) CA2964309A1 (es)
ES (1) ES2570452B1 (es)
WO (1) WO2016059269A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3833662B1 (en) 2018-08-20 2024-01-17 Janssen Pharmaceutica NV Inhibitors of keap1-nrf2 protein-protein interaction
ES2946307A1 (es) * 2022-01-14 2023-07-14 Consejo Superior Investigacion Compuestos inductores de nrf2 e inhibidores de mao-b para el tratamiento de la enfermedad de parkinson
ES2957638A1 (es) * 2022-06-15 2024-01-23 Univ Rey Juan Carlos (e)-3-(4-hidroxi-3-metoxifenil)-acrilato de 3-(2-acetamidoetil)-1h-indol-5-ilo para uso en la prevencion y/o tratamiento de la hipertension arterial y las alteraciones cardiovasculares asociadas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
AU7261196A (en) * 1995-10-10 1997-04-30 Eli Lilly And Company N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists
NZ527815A (en) * 2001-03-29 2005-05-27 Lilly Co Eli N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
CA2827990A1 (en) * 2011-02-25 2012-08-30 The Johns Hopkins University Chalcone derivatives as nrf2 activators
US8916604B2 (en) * 2011-05-31 2014-12-23 Rutgers, The State University Of New Jersey Compositions and methods for epigenetic modification of nucleic acid sequences

Also Published As

Publication number Publication date
CA2964309A1 (en) 2016-04-21
EP3208262A4 (en) 2018-05-02
ES2570452B1 (es) 2017-04-19
ES2570452A1 (es) 2016-05-18
EP3208262A1 (en) 2017-08-23
US20180105492A1 (en) 2018-04-19
WO2016059269A1 (es) 2016-04-21

Similar Documents

Publication Publication Date Title
EP3140403A4 (en) Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system
EP3359662A4 (en) COMPOSITIONS AND METHODS OF TREATING HUNTINGTON DISEASE AND RELATED DISEASES
WO2015175642A3 (en) Methods and compositions for prevention or treatment of a disease
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
WO2015153760A3 (en) Methods and compositions for prevention or treatment of a nervous system disorder
EP3215191A4 (en) Aadc polynucleotides for the treatment of parkinson's disease
WO2015153800A3 (en) Compositions for modulating sod-1 expression
BR112016023382A2 (pt) composto, medicamento, método para inibir lsd1, e, uso de um composto
CL2014000806A1 (es) Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple.
WO2015108490A3 (en) Heteroaryl alkyne derivatives and uses thereof
WO2015184257A3 (en) Small molecule transcription modulators of bromodomains
WO2015200790A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
WO2013033037A3 (en) Novel antiprion compounds
WO2015116663A8 (en) Heteroaryl amides as inhibitors of protein aggregation
WO2014151456A3 (en) Treatment of inflammatory diseases
EP3377118A4 (en) METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
NZ709399A (en) Method of treatment of hypoxia inducible factor (hif)-related conditions
WO2016059269A8 (es) Compuestos derivados de acrilato de 3-alouilamino-1h- indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
WO2015155680A3 (en) Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors
EA201790315A1 (ru) Модуляторы x-рецепторов печени
WO2015077535A3 (en) Novel methods for treating neurodegenerative diseases
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MD4780B1 (ro) Urei asimetrice p-substituite şi utilizările medicale ale acestora
MX358078B (es) Acido (s)-3'-metil-abscisico y esteres del mismo.
WO2015079067A3 (en) Various compounds as autophagy stimulants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15851060

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15518223

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2964309

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015851060

Country of ref document: EP